Literature DB >> 16956353

Outcomes in patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection.

Nivedita Bhatta Dhar1, Steven C Campbell, Craig D Zippe, Ithaar H Derweesh, Alwyn M Reuther, Amr Fergany, Eric A Klein.   

Abstract

OBJECTIVES: To evaluate the rates of local and systemic progression (LP and SP), recurrence-free survival and overall survival for patients with urothelial carcinoma of the bladder with limited pelvic lymph node dissection (PLND) in 1987-2000. PATIENTS AND METHODS: A consecutive series was analysed of 385 patients (median age 61.9 years, range 30.7-83.8) treated by limited bilateral PLND and radical cystectomy (RC) between 1987 and 2000, with negative surgical margins on final pathology. All patients were staged N0M0 before RC, and none received neoadjuvant radiotherapy or chemotherapy. The boundaries of the limited PLND were the pelvic side-wall between the genitofemoral and obturator nerves, and bifurcation of iliac vessels to the circumflex iliac vein. LP was defined as a radiographic soft-tissue density of > or = 2 cm below the bifurcation of the aorta. Pathological characteristics, based on the 1997 Tumour-Nodes-Metastasis system, recurrence patterns, and recurrence-free and overall survival, were determined. RESULTS The median (range) overall follow-up was 45.1 (1.1-165.6) months; the number of lymph nodes (LNs) reported per patient was 12 (2-32). Of the 385 patients, 130 (33.8%) had evidence of LP and 60 (15.6%) of SP. The 5-year recurrence-free and overall survival rates were both 71% for patients with organ-confined, N0 tumours, and 23% and 26% for unconfined, N0 tumours. Positive LNs were found in 45 (12%) patients, who had a recurrence-free and overall survival rate of 9% at 5 years.
CONCLUSION: Compared with published reports of similar cohorts of patients managed with RC and extended PLND, the present study suggests that limited PLND is associated with suboptimal staging, greater rates of LP, and lower rates of recurrence-free survival, particularly for patients with unconfined or LN-positive disease.

Entities:  

Mesh:

Year:  2006        PMID: 16956353     DOI: 10.1111/j.1464-410X.2006.06502.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  5 in total

Review 1.  The survival benefit of lymph node dissection at the time of removal of kidney, prostate and urothelial carcinomas: what is the evidence?

Authors:  Karim Bensalah; Morgan Roupret; Evanguelos Xylinas; Shahrokh Shariat
Journal:  World J Urol       Date:  2013-04-16       Impact factor: 4.226

Review 2.  [The significance of extended pelvic lymphadenectomy in bladder cancer].

Authors:  M Autenrieth; M Retz; J E Gschwend
Journal:  Urologe A       Date:  2011-12       Impact factor: 0.639

Review 3.  Radical transurethral resection alone, robotic or partial cystectomy, or extended lymphadenectomy: can we select patients with muscle invasion for less or more surgery?

Authors:  Eugene K Cha; Timothy F Donahue; Bernard H Bochner
Journal:  Urol Clin North Am       Date:  2015-02-28       Impact factor: 2.241

4.  [Muscle-invasive urothelial carcinoma of the bladder. Detection and topography of micrometastases in lymph nodes].

Authors:  M Autenrieth; R Nawroth; S Semmlack; J E Gschwend; M Retz
Journal:  Urologe A       Date:  2008-09       Impact factor: 0.639

5.  Pelvic lymphadenectomy in the treatment of invasive bladder cancer: literature review.

Authors:  Ehab A Elzayat; Ali A Al-Zahrani
Journal:  Adv Urol       Date:  2011-08-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.